Biotech startup Lantern Pharma’s IPO yields $26 million for its cancer drug development Jun 16 Written by Health Wildcatters Health Wildcatters Previous Previous Northwestern Mutual invests in Dallas health startup targeting millennials Next Next Dallas-Based Lantern Pharma is Going Public
Biotech startup Lantern Pharma’s IPO yields $26 million for its cancer drug development Jun 16 Written by Health Wildcatters Health Wildcatters